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Abstract
Introduction: Adrenal tumours can produce specific hormones and cause characteristic symptoms. The majority of adrenal incidentalomas 
are clinically silent, but some may be malignant or pose other potential threats to life. 
Chromogranin A (CgA) is the main, nonspecific marker of neuroendocrine tumours (NET). In the adrenals, CgA is produced by chromaf-
fin cells localised in the adrenal medulla. Therefore its measurement in blood might be used as a screening test for pheochromocytoma 
after the exclusion of other various causes of an increased CgA level. 
The aim of our study was to investigate plasma CgA concentration in various adrenal tumours.
Material and methods: EDTA2K plasma samples were obtained from 195 patients with adrenal tumours and from 50 blood donors. CgA 
was measured in plasma-EDTA2K by immunoradiometric (IRMA) method.
Results: In the majority of patients with adrenal tumours not derived from neuroendocrine cells (chromaffin cells), except those with 
significant hypercortisolaemia and some patients with adrenal carcinoma, the plasma CgA concentrations were below the cut-off value. 
In adrenal tumours derived from chromaffin cells (pheochromocytoma), CgA levels were markedly elevated.
Conclusion: In differential diagnosis of adrenal tumours, non-increased CgA level might be useful initial screening evidence for the 
exclusion of pheochromocytoma. (Endokrynol Pol 2013; 64 (5): 358–362)
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Streszczenie
Wstęp: Guzy nadnercza mogą produkować specyficzne hormony i powodować charakterystyczne objawy kliniczne, ale przeważająca 
część guzów, zwłaszcza typu incydentaloma, jest niema klinicznie, chociaż część z nich może mieć charakter złośliwy albo stanowić 
inne potencjalne zagrożenie dla życia. Chromogranina A (CgA) jest głównym, niespecyficznym markerem guzów neuroendokrynnych 
(NET). Jest ona produkowana także między innymi przez komórki chromafinowe rdzenia nadnerczy i jej pomiar we krwi mógłby być 
użytecznym testem przesiewowym dla pheochromocytoma po wykluczeniu innych możliwych przyczyn podwyższonego stężenia CgA. 
Celem naszej pracy było zbadanie osoczowego stężenia CgA w różnych guzach nadnerczy.
Materiał i metody: Materiałem do badania były próbki osocza (EDTA₂K) pozyskane od 195 pacjentów skierowanych z powodu guza 
nadnercza oraz od 50 dawców krwi. Stężenie CgA oznaczono w osoczu EDTA₂K metodą immunoradiometryczną (IRMA).
Wyniki: Stężenie CgA w większości przypadków guzów nie wywodzących się z komórek neuroendokrynnych nadnercza oraz w części 
przypadków raka nadnerczy, z wyjątkiem tych ze znaczącą hyperkortyzolemią, było poniżej wartości cut-off. W guzach wywodzących 
się z komórek chromafinowych nadnercza (pheochromocytoma) obserwowano znacząco podwyższone stężenia CgA. 
Wnioski: We wstępnej diagnostyce różnicowej guzów nadnerczy, stwierdzenie prawidłowego stężenia CgA może być pomocnym mar-
kerem dla wykluczenia pheochromocytoma. (Endokrynol Pol 2013; 64 (5): 358–362)
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Introduction
Adrenal tumours can produce specific hormones and 
cause characteristic symptoms. The majority of inci-
dentally found adrenal tumours are clinically silent, 
however some of them may be malignant or pose other 
potential threats to life [1–3]. 
Chromogranin A (CgA) is the main, nonspecific 
marker of neuroendocrine tumours (NET) [4, 5]. It is 
a hydrophylic glycoprotein belonging to the chromogranin / 
/secretogranin family - acid secretory proteins which 
are co-stored in secretory granules and co-released with 
resident hormones from neuroendocrine cells [6]. In 
adrenals, CgA is produced by chromaffin cells localised in 
the adrenal medulla and released into the blood. Therefore 
its measurement might be used as a screening test for 
pheochromocytoma after the exclusion of other various 
causes of an increased CgA level [7, 8]. 
The aim of our study was to investigate plasma CgA 
concentration in various adrenal tumours.
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Material and methods
We investigated 195 patients (62 males and 133 females; 
mean ± SD age 57 ± 14, range 18–82 years) with adrenal 
masses which, mostly, were incidentally discovered 
during imaging procedures: ultrasonography (USG), 
computed tomography (CT), or magnetic resonance 
imaging (MRI). 
Routine hormonal determinations included: ACTH, 
cortisol (before and after 1 mg dexamethasone suppres-
sion test- DST), urine free cortisol, 17-OHCS and 17-KS 
in 24 hour urine, (and if indicated) androstendione, 
DHEA-S, and 17-hydroxyprogesterone. In patients 
with hypertension: concentration of aldosterone in 
serum and 24 hour urine, plasma renin activity (PRA) 
after a night’s rest in supine position (0hr) and after 
two hours in an upright position (2hr), metanephrines 
(24hr urine). CT (or MRI) of adrenals with i.v. contrast 
was performed in all patients and 123-iodine-labelled 
metaiodobenzylguanidine (123-I-MIBG) scintigraphy 
only in some patients suspected of pheochromocytoma. 
The control group consisted of 50 blood donors (mean 
± SD age 33 ± 9, range 19–52 years). 
Venous blood was centrifuged (ten minutes, 3,500 rpm) 
and plasma (EDTA2K) was frozen at –30°C and stored 
until assayed. 
Chromogranin A was measured by the immu-
noradiometric method (CIS bio, France). Analytical 
sensitivity was 1.5 ng/mL. The cut-off value suggested 
by the manufacturer for plasma-EDTA2K is 150 ng/mL. 
Intra-assay CV values were: 6% for 30 ng/mL, 3.8% for 
144 ng/mL, and 2.2% for 996 ng/mL. Inter-assay CV 
values were: 8.5% for 29 ng/mL, 5.7% for 144 ng/mL 
and 5.3% for 996 ng/mL. 
Metanephrines were measured by the high-perfor-
mance liquid chromatography (HPLC) method in 24hr 
urine (at least two times) by a local laboratory. Reference 
value was: 100–1,000 μg/24hr.
The study was approved by the Bioethics Commit-
tee of The Centre of Postgraduate Medical Education. 
Data is expressed as median and as a range. The 
Kruskal-Wallis test, followed by Dunn’s post-hoc test 
and the multiple Mann-Whitney U-test, were performed 
to estimate differences between groups. A p-value of < 
0.05 was considered to be significant and p < 0.001 highly 
significant. All statistical analyses were performed using 
statistical software (PQStat ver. 1.4.2.324).
Results
In tumours derived from adrenal chromaffin cells, 
pheochromocytomas (n = 8), the median of CgA value 
was 660 ng/mL (range 266–1,478 ng/mL). The main 
findings from patients with confirmed pheochromo-
cytoma are presented in Table I. Plasma CgA levels 
were significantly higher in patients with pheochro-
mocytoma (p < 0.0001) in relation to another group 
of patients with adrenal tumours (Fig.1). Notably, in 
Table I. Patients with confirmed pheochromocytoma
Tabela I. Pacjenci z potwierdzonym pheochromocytoma
N° Sex/age CgA  
[ng/mL]
Metanephrines 
(urine)  
[μg/24 h]
Confirmation
1. M/63 428  1,500 123-I-MIBG 
scintigraphy 
Histopathology 
2. M/56  882  1,208 Histopathology
3. F/57 297  1,572 Histopathology
4. F/28 266  1,458 Histopathology
5. F/71 962  1,750 Histopathology
6. M/59 438  2,916 Histopathology
7. F/46 1,069  6,974 123-I-MIBG 
scintigraphy
Histopathology
8. F/53 1,478  24,848 Histopathology
Figure 1. Plasma CgA concentartion in patients with 
pheochromocytoma, active cortical adenomas, silent incidentalomas, 
adrenal carcinomas and in the control group
Rycina 1. Stężenie wyników osoczowego CgA w grupie pacjentów 
z pheochromocytoma, czynnymi i nieczynnymi guzami kory 
nadnerczy, w rakach nadnerczy  oraz w grupie kontrolnej
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two observed cases of paraganglioma located outside 
the adrenal glands, CgA levels were not increased. In 
the control group consisting of blood donors (n = 50), 
the mean ± SD plasma CgA level was 59 ± 18 ng/mL 
(range 23–153 ng/mL).
Excluding the cases of pheochromocytoma, the 
median of plasma CgA concentrations in hormonally 
active adenomas (n = 40) was 54 ng/mL (range 20– 
–319 ng/mL). In this group (n = 3), higher concen-
trations of CgA (range 150–319 ng/mL) were noted 
mainly in some of the adenomas secreting cortisol. In 
adrenal carcinoma (n = 20), the median of CgA was 
96 ng/mL (range 34–319 ng/mL) and, again, in three of 
them with marked hypercortisolaemia, CgA also appeared 
markedly higher (range 152–319 ng/mL). In 113 cases 
with hormonally silent incidentalomas, the median 
concentration of CgA was 68 ng/mL (range 20–167 ng/mL); 
in other rare tumours of adrenal glands (n = 12) (my-
elolipoma, angiomyolipoma, paraganglioma and me-
tastasis of other neoplasms), the median was 74 ng/mL 
(range 40–138 ng/mL). The results are presented in 
Table II.
Discussion
Adrenal incidentaloma, usually defined as an adrenal 
mass unexpectedly detected by imaging procedures 
(USG, CT, MRI), can be hormonally silent or active and 
benign or malignant. Active adrenocortical adenomas 
may secrete cortisol, androgens, or aldosterone [9]. 
Pheochromocytoma, a catecholamine-producing 
tumour, with preferential localisation in the adrenal 
medulla, occurs in 0.1–0.6% patients of arterial hyper-
tension [10, 11] and in about 2–5% of patients with 
adrenal incidentaloma [12]. Biochemical screening 
of pheochromocytoma in daily practice is based on 
24-hour urine metanephrines and catecholamines. Re-
cently CgA measurement was proposed as an additional 
means of investigation in this pathology. According to 
Giovanella et al. [13], sensitivity and specificity of CgA 
in pheochromocytoma is 92–96%. Unger et al. however 
reported lower sensitivity and specificity (around 74%) 
for a CgA threshold value of 215 μg/L [14]. 
In our study, the CgA concentration was above the 
cut-off value in eight observed cases of pheochromo-
Table II. CgA in adrenal tumours
Tabela II. CgA w guzach nadnerczy
CgA in adrenal tumours n  Median Range  
(min/max)  
[ng/mL]
 p value
Hormonally active medullary adenoma:
Pheochromocytoma
 
8 660 266–1,478
Hormonally active cortical adenomas:
Cortisol
     CgA ≥ cut-off 
     CgA < cut-off
Aldosterone (aldosteronoma or adrenal hyperplasia)
Androgens
Mixed adenomas (cortisol/androgens)
40
 
3
13
14
8
2
54
 
225
53
47
51
63
20–319
 
150–319
21–127
20–158
 31–66
54–72
p < 0.0001*
Adrenal carcinoma:
with hypercortisolaemia
without hypercortisolaemia
20
7**
 13
96 
96
 96
34–319
54–319
34–196
p < 0.0001*
Incidentaloma (silent hormonally) 113 68 27–167 p < 0.0001*
Rare tumours of adrenal gland:
Angiomyolipoma
Myelolipoma
Metastasis
Paraganglioma (location outside of the adrenal)
 
12 74 40–138 p < 0.0002*
Control group (blood donors) 50 59 23–153 p < 0.0001*
*pheochromocytoma v. non-chromaffin adrenal tumours [Mann-Whitney U-test]; **in three of seven cases with marked hypercortisolaemia, CgA appeared markedly 
higher (range 152–319 ng/mL)
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cytoma and ranged 266–1,478 ng/mL (mean ± SD 727 
± 436 ng/mL). In the study of Bílek et al., who used 
the same CgA immunoradiometric method, the mean 
concentration of plasma CgA ± SD in patients with 
pheochromocytoma was 635 ± 451 ng/mL [15]. In 
interpreting the raised CgA level, we must consider 
the possible influence on CgA of some drugs (mainly 
proton pump inhibitors) and coincidental diseases 
(for example: atrophic gastritis, renal or hepatic insuf-
ficiency, and prostatic carcinoma) [7]. It is important 
to note that pheochromocytoma should be excluded 
before any invasive diagnostic or therapeutic pro-
cedure is undertaken to avoid the development of 
catecholaminergic crisis. It has been reported that in 
clinically silent cases of pheochromocytoma, after the 
administration of glucocorticoids in a dose exceeding 
1 mg of dexamethasone, there is a potential threat 
of severe hypertensive crisis, with life-threatening 
symptoms (low dose DST — 1 mg orally — has not 
been associated with such crisis [16]). 
Therefore, special care is necessary while planning 
the performance of high dose dexamethasone sup-
pression tests in insufficiently diagnosed cases. Similar 
caution is advised when prescribing glucocorticoids as 
a pre-treatment before CT or MRI in patients allergic 
to contrast dye. For the above reasons, an additional 
test helping to confirm or exclude pheochromocytoma 
among patients with an asymptomatic adrenal tumour 
seems warranted.
In two cases of incidentaloma with concomitant para-
ganglioma, localised in one case very near the right adre-
nal gland, and in the second case in the pericardium, the 
levels of CgA were below the cut-off value. According to 
Seregni et al. [17], CgA levels are elevated only in 40–50% 
of extra-adrenal paraganglioma tumours. 
Most adrenal incidentalomas are benign adrenal 
adenomas (they account for about 80-87% of all tu-
mours), and for the most part they are non-functioning 
[18]. Cortisol secreting adenomas are the most common 
functional tumours [19].
In our study, in the majority of silent and hormo-
nally active adenomas (secreting cortisol, androgens 
or aldosterone), adrenal carcinomas, and in some rare 
tumours (angiomyolipoma, myelolipoma, metastasis 
of various neoplasms), the CgA levels were below or 
around the cut-off value. A similar observation was 
presented in the study performed by Giovanelli [20]. In 
some cases of hormonally active adenomas and adrenal 
carcinomas secreting large amounts of cortisol, CgA 
levels were above the cut-off value, but not as high as 
in the observed cases of pheochromocytoma.
CgA measurements were also considered as 
a possible useful parameter, instead of or in addition to 
cortisol, in assessing the selectivity in adrenal venous 
sampling in cases of primary aldosteronism. Seccia et 
al., however, does not support such a method, perhaps 
with the exception of rare cases of a tumour secreting 
both aldosterone and cortisol [21]. 
Chromogranin A is usually included in a panel of 
immunohistochemical markers for studying operated 
adrenal tumours. In a comprehensive study performed 
by Weissferdt et al. [22], however, only two of 40 cases 
of adrenal cancer showed positivity for CgA. Positive 
immunohistochemical staining for CgA was also re-
ported in an extremely rarely diagnosed adrenocortical 
oncocytoma [23]. 
Conclusions
 — In the majority of patients with adrenal tumours 
not derived from neuroendocrine cells (chromaf-
fin cells), and in some with adrenal carcinoma, 
except those with significant hypercortisolaemia, 
plasma CgA concentrations were below the cut-
off value. 
 — In adrenal tumours derived from chromaffin cells 
(pheochromocytoma), CgA levels were markedly 
increased. 
 — In preliminary differential diagnosis of adrenal tu-
mours, a non-increased CgA level might be useful 
screening evidence for the exclusion of pheochro-
mocytoma.
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